Loading...
•
Jun 30, 2022
Arcellx Q2 2021 Earnings Report
Arcellx reported business highlights and financial results.
Key Takeaways
Arcellx reported its Q2 2022 financial results, highlighting the completion of an upsized follow-on offering, presentation of CART-ddBCMA Phase 1 expansion trial data, and preclinical results from CART-ddBCMA published in Molecular Cancer Therapeutics.
Completed an upsized follow-on offering of common stock, raising $128.8 million in gross proceeds.
Presented robust long-term responses from its CART-ddBCMA Phase 1 expansion trial at the 2022 ASCO Annual Meeting.
Preclinical results from CART-ddBCMA were published in Molecular Cancer Therapeutics.
First patient dosed in ACLX-001, a Phase 1 study utilizing Arc-SparX technology.
Arcellx
Arcellx
Forward Guidance
Arcellx looks forward to presenting at ESMO, initiating the Phase 2 pivotal CART-ddBCMA trial, presenting longer-term patient data from the Phase 1 CART-ddBCMA expansion trial, and initiating the Phase 1 ARC-SparX clinical trial of ACLX-002.
Positive Outlook
- Presenting an encore presentation of CART-ddBCMA Phase 1 study at ESMO.
- Initiating Phase 2 pivotal CART-ddBCMA (iMMagine) trial in patients with r/r MM.
- Presenting longer-term patient data from Phase 1 CART-ddBCMA expansion trial in r/r MM.
- Initiating Phase 1 ARC-SparX clinical trial of ACLX-002 in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Scaling the business and advancing the novel platform to help as many patients as possible.
Challenges Ahead
- Risks associated with the timing and outcomes of clinical trials.
- Uncertainties regarding the potential impact of product candidates and platforms.
- Risks related to the timing of achievement of milestones.
- Risks associated with the ability to fund operations.
- Risks and uncertainties that may be found in the company's filings with the SEC.